Insilico Medicine vs Universal Health Services
Side-by-side comparison of AI visibility scores, market position, and capabilities
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
Universal Health Services (UHS) reported ~$15.7B revenue in FY2024. Leading hospital and behavioral health facility operator with 350+ acute care and psychiatric hospitals in the U.S. HQ: King of Prussia, PA.
About
Universal Health Services, Inc. is one of the largest hospital and behavioral health facility operators in the United States, providing acute care hospital services, inpatient and outpatient behavioral health services, and specialized medical services. Founded in 1978 by Alan Miller, UHS operates approximately 350+ facilities — including general hospitals, surgical hospitals, freestanding emergency departments, and over 200 behavioral health centers treating mental illness and substance abuse disorders. The company operates across 37 states, Washington, D.C., and the United Kingdom.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.